Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data

Journal of Biomedical Informatics

Volumn 43, Issue 3, 2010, Pages 376-384

  Yang, Xinan ^a   Huang, Yong ^a   Crowson, Matthew ^a   Li, Jianrong ^a   Maitland, Michael L ^a   Lussier, Yves A ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adverse event; Computational modeling; Kinase inhibitor; Kinome; Toxicity; Translational bioinformatics

Indexed keywords

ADVERSE EVENTS; COMPUTATIONAL MODELING; KINASE INHIBITOR; KINASE INHIBITORS; KINOME;

BIOINFORMATICS; DISSOCIATION; ENZYME INHIBITION; FORECASTING; LEAD REFINING; MATHEMATICAL MODELS; PROTEINS; REFINING; TARGETS; TOXICITY;

COMPUTATIONAL METHODS;

COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR; PROTEIN KINASE INHIBITOR; PROTEIN KIT; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; PROTEIN KINASE;

ADVERSE DRUG REACTION; ARTICLE; ASTHENIA; BINDING AFFINITY; BIOINFORMATICS; CLINICAL RESEARCH; COMPUTER MODEL; CORRELATION ANALYSIS; DATA BASE; DIARRHEA; DISSOCIATION CONSTANT; DRUG SURVEILLANCE PROGRAM; EDEMA; ENZYME INHIBITION; FATIGUE; FISHER EXACT TEST; GENOME; HUMAN; IN VITRO STUDY; KINOME; MEDICAL LITERATURE; NAUSEA; PREDICTION; PRIORITY JOURNAL; PUBLICATION; QUANTITATIVE ANALYSIS; RASH; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; VOMITING; BIOLOGY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FACTUAL DATABASE; PROCEDURES;

CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG TOXICITY; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS;

EID: 77952742187     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2010.04.006     Document Type: Article

References (32)

1. Druker B.J., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 23 (2006) 2408-2417
2. Berman E., et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354 19 (2006) 2006-2013
3. Kerkela R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12 8 (2006) 908-916
4. Maitland M.L., and Ratain M.J. Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med 145 9 (2006) 702-703
5. Manning G., et al. The protein kinase complement of the human genome. Science 298 5600 (2002) 1912-1934
6. Muster W., et al. Computational toxicology in drug development. Drug Discov Today 13 7-8 (2008) 303-310
7. Agarwal P., and Searls D.B. Literature mining in support of drug discovery. Brief Bioinform (2008)
8. Karaman M.W., et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26 1 (2008) 127-132
9. Hansen N.T., Brunak S., and Altman R.B. Generating genome-scale candidate gene lists for pharmacogenomics. Clin Pharmacol Ther 86 2 (2009) 183-189
10. Bender A., et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2 6 (2007) 861-873
11. Ji Z.L., et al. Drug adverse reaction target database (DART): proteins related to adverse drug reactions. Drug Saf 26 10 (2003) 685-690
12. Apic G., et al. Illuminating drug discovery with biological pathways. FEBS Lett 579 8 (2005) 1872-1877
13. Fliri A.F., Loging W.T., and Volkmann R.A. Analysis of system structure-function relationships. ChemMedChem 2 12 (2007) 1774-1782
14. Garten Y., and Altman R.B. Pharmspresso: a text mining tool for extraction of pharmacogenomic concepts and relationships from full text. BMC Bioinform 10 Suppl. 2 (2009) S6
15. Liebovitch L.S., Tsinoremas N., and Pandya A. Developing combinatorial multi-component therapies (CMCT) of drugs that are more specific and have fewer side effects than traditional one drug therapies. Nonlinear Biomed Phys 1 1 (2007) 11
16. Campillos M., et al. Drug target identification using side-effect similarity. Science 321 5886 (2008) 263-266
17. Kuhn M., et al. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res 36 (2008) D684-D688 Database issue
18. Yildirim M.A., et al. Drug-target network. Nat Biotechnol 25 10 (2007) 1119-1126
19. Keiser M.J., et al. Predicting new molecular targets for known drugs. Nature 462 7270 (2009) 175-181
20. Thomson Healthcare Staff. Physicians' Desk Reference 2008. Matthews Medical Books; 2008.
21. Storey J.D. A direct approach to false discovery rates. J Roy Stat Soc Ser B 64 (2002) 479-498
22. Storey J.D. The positive false discovery rate: a Bayesian interpretation and the q-value. Ann Stat 31 (2003) 2013-2035
23. Becker K.G., et al. PubMatrix: a tool for multiplex literature mining. BMC Bioinform 4 (2003) 61
24. Fisher R.A. On the Interpretation of χ2 from contingency tables, and the calculation of P. J Roy Stat Soc 85 1 (1922) 87-94
25. Warm M., et al. Side-effects of pre-operative epirubicin-paclitaxel therapy in primary breast cancer associated with tumor biology. Anticancer Res 29 7 (2009) 2675-2680
26. Lacouture M.E., et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18 4 (2010) 509-522
27. Cohen E.E., et al. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol (2009)
28. Perez-Soler R., and Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 23 22 (2005) 5235-5246
29. Wacker B., et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13 13 (2007) 3913-3921
30. Fojo T. Commentary: novel therapies for cancer: why dirty might be better. Oncologist 13 3 (2008) 277-283
31. Miller M.L., et al. Linear motif atlas for phosphorylation-dependent signaling. Sci Signal 1 35 (2008) ra2
32. Shuler ML, McAuliffe GJ, Tatosian DA. Animal surrogate systems for toxicity testing. In: Bowlin GL, Wnek G, editors. Encyclopedia of biomaterials and biomedical engineering, March. New York; 2006.